# Tetra Discovery Partners

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tetra-discovery-partners

- Industry: Healthcare
- Headquarters: Grand Rapids, US
- Website: www.tetradiscovery.com
- Total disclosed funding: $6M
- Latest round: Series A (Nov 29, 2016)
- Investors on record: 7

## About

Tetra Discovery Partners is a pharmaceutical company focusing on the development of innovative treatments for neurodegenerative diseases, primarily targeting Alzheimer’s and Fragile X Syndrome. Their work aims to address critical unmet medical needs in healthcare.Founded in 2010 and headquartered in Grand Rapids, US, Tetra Discovery Partners specializes in developing pharmaceutical solutions for neurodegenerative disorders. The company has undergone strategic pivots but remains focused on its core mission. Mark Gurney leads the company, bringing a wealth of experience in biotechnology. Tetra raised USD 5.00 mn in Series A funding on November 29, 2016, co-led by Apjohn Ventures and Grand Angels, alongside participation from other investors, including the Alzheimer's Drug Discovery Foundation and Dolby Family Ventures. Over its operation, Tetra has engaged in six notable funding deals.Tetra Discovery Partners develops therapeutics focusing on neurodegenerative diseases, particularly targeting conditions like Alzheimer’s and Fragile X Syndrome. Their therapeutic pipeline aims to improve patient outcomes through innovative drug development tailored to address specific disease mechanisms, which are critical in treating complex health conditions.Tetra Discovery Partners generates revenue through the commercialization of its pharmaceutical products directly to healthcare providers, hospitals, and specialty pharmacies. Revenue is primarily derived from product sales, supported by partnerships that enhance market reach and availability of their treatments.Looking ahead, Tetra Discovery Partners plans to expand its product pipeline with several new therapeutics aimed at neurodegenerative diseases, with anticipated launches in the coming years. They are focused on entering new markets, particularly in Europe and Asia, by 2025. The recent Series A funding of USD 5.00 mn will be utilized to support these initiatives, including research and development to accelerate their product offerings and geographical expansion.

## Funding rounds

- Series A, Nov 29, 2016, $5M — Apjohn Ventures, Grand Angels, Dolby Family Ventures, Alzheimer's Drug Discovery Foundation
- Seed, Sep 30, 2013, $1M — Ann Arbor SPARK, Grand Angels, Michigan Emerging Technology Fund, Biosciences Research & Commercialization Center

## Investors

- Ann Arbor SPARK (https://capitalatlas.ai/funds/ann-arbor-spark) — Seed
- Grand Angels — Seed, Series A
- Michigan Emerging Technology Fund — Seed
- Biosciences Research & Commercialization Center (https://capitalatlas.ai/funds/biosciences-research-commercialization-center) — Seed
- Apjohn Ventures (https://capitalatlas.ai/funds/apjohn-ventures) — Series A
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A
- Alzheimer's Drug Discovery Foundation — Series A